Project Grant HT94252310904
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$395K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This $834,798 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports PET imaging research of HIF 2A in renal cancer at The University of Texas Southwestern Medical Center in Dallas, Texas. The research project aims to develop new diagnostic and treatment approaches for kidney cancer, which is a key focus area for this Defense Department program. The award will fund basic, translational, and clinical research...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,107,000 three-year Project Grant to The University of Texas Southwestern Medical Center in Dallas, TX. The grant, effective September 1, 2023, will fund research to characterize the epigenetic and metabolic vulnerabilities in clear cell renal cell carcinoma (ccRCC) with VHL gene deficiencies, and explore the therapeutic potential of these findings. The University of Texas System will...
This federal Project Grant award for $968,904.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Texas Southwestern Medical Center (UT Southwestern) to target the DNA damage response as a potential treatment for clear cell renal cell carcinoma. The project will be conducted at UT Southwestern's facilities in Dallas, Texas over a 4-year period from July 1, 2024 to June 30, 2028. This...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $766,965 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 30, 2024. The grant supports a 3-year research project to develop new methods for targeting kidney cancer tumors in order to improve immunotherapy outcomes. The research aims to identify tumor surface biomarkers that can be leveraged to enhance the effectiveness of cancer...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...
The University of Texas Southwestern Medical Center (UT Southwestern) has been awarded a Project Grant for $1,180,962.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 30, 2024, will support a research project titled "TUMOR SURFACE BIOMARKER-INDEPENDENT TARGETING OF KIDNEY CANCER TO IMPROVE IMMUNOTHERAPY" over a performance period ending on June 29, 2027. The grant funding will enable UT...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...